Skip to main content
Erschienen in: Pediatric Rheumatology 1/2011

Open Access 01.12.2011 | Poster presentation

Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD

verfasst von: AM Boldingh, EB Nordal

Erschienen in: Pediatric Rheumatology | Sonderheft 1/2011

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

There is a risk of developing serious complications of varicella zoster infection (VZI) in juvenile idiopathic arthritis (JIA) patients receiving disease modifying antirheumatic drugs (DMARD) including methotrexate and biologic agents [1, 2]. Varicella zoster (VZ) immune status should therefore be checked in all children before starting such therapy. Seronegative children mostly receive varicella zoster vaccine (VZV). Vaccination may prevent worried parents and reduce the need for VZ immunoglobulin, intravenous acyclovir treatment and hospitalization.

Aim

We wanted to investigate the VZ immunity and response to VV in patients with JIA treated with DMARD in Northern Norway.

Methods

All patients with a new diagnosis of JIA between 1997-2010 treated with DMARD in two counties of Northern Norway were included. The patients were identified using a prospectively collected study database. We investigated retrospectively the patients` charts for VZ serological status, the response rate to VV, the incidence and treatment of VZI. If the file did not contain adequate information on the patients who were non-immune to VZ, we contacted the patient/parents to complete a telephone survey.

Results

Of the total study group of 150 patients, 71 patients were treated with DMARD. Before starting treatment 23 of the 71 patients (32%) had negative VZ IgG titer. VZV was given to 21 of these before starting treatment. VZ IgG status showed a positive titer in 5 patients after first VZV, 2 were not checked and 2 had an intermediate titer. All, except one, of the post-vaccinated VZ IgG negative patients received a second dose. No serious complications of the VZV were seen. After some months 5 of the 15 (33%) seropositive children and 1 in the intermediate group (50%) developed VZI. One child developed mild VZI immediately after VZV, the other children developed VZI 0.5, 1.3, 4.5 and 10,5 years after VZV. Three of these six children with VZI received acyclovir treatment. None of the patients had serious complication or severe illness.

Conclusion

After VZV 33% of the children with positive VZ IgG titer developed VZI. VZV may give a milder infection in vaccinated children, as no serious complications or servere illness was observed in any of the children who developed VZI.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Literatur
1.
Zurück zum Zitat Cerrasco R, Smith JA, Lovell D: Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs. 2004, 6 (3): 137-46. 10.2165/00148581-200406030-00001.CrossRef Cerrasco R, Smith JA, Lovell D: Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs. 2004, 6 (3): 137-46. 10.2165/00148581-200406030-00001.CrossRef
2.
Zurück zum Zitat Gluck T, Muller-Ladner U: Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008, 46: 1459-65. 10.1086/587063.CrossRefPubMed Gluck T, Muller-Ladner U: Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008, 46: 1459-65. 10.1086/587063.CrossRefPubMed
Metadaten
Titel
Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD
verfasst von
AM Boldingh
EB Nordal
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Pediatric Rheumatology / Ausgabe Sonderheft 1/2011
Elektronische ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-9-S1-P132

Weitere Artikel der Sonderheft 1/2011

Pediatric Rheumatology 1/2011 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Häufigste Gründe für Brustschmerzen bei Kindern

06.05.2024 Pädiatrische Diagnostik Nachrichten

Akute Brustschmerzen sind ein Alarmsymptom par exellence, schließlich sind manche Auslöser lebensbedrohlich. Auch Kinder klagen oft über Schmerzen in der Brust. Ein Studienteam ist den Ursachen nachgegangen.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.